Surgery Committee

FRIDAY, OCTOBER 9 • 8:00 – 9:30 AM CT • COMISKEY (CONCOURSE LEVEL, WEST TOWER)

Agenda

Update from Executive Officer

Lisa A. Kachnic, MD, FASTRO, Chair, Radiation Oncology, Columbia University

Update on Clinical Trials Targeting KRAS (Virtual Presentation)

Wungki Park, MD, Assistant Attending Physician, Hepatopancreaticobiliary Section Gastrointestinal Oncology Section, Memorial Sloan Kettering Cancer Center, New York NY

Trials and Projects in Development and Ongoing Trials

An Update on S2408: A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula.

Jonathan Sham, MD, University of Washington, Seattle WA

An Update on S2605: A Phase III Trial of Preoperative Chemotherapy vs Surgery First (CRS-HIPEC) for High-Grade Appendiceal Cancer.

Sameer Patel, MD, University of Cincinnati, Cincinnati OH

SWOG 2703: Randomized Phase II Trial of Neoadjuvant Dostarlimab Versus Pot-Operative Standard Pathway of Adjuvant FOLFOX/ CAPOX Plus Atezolizumab for Localized MSI-H/dMMR Colon Cancer

Emerson Y. Chen, MD, MCR, Knight Cancer Institute, Oregon Health and Science University

VANGUARD: Value of Adjuvant Non-cross-resistant therapy in Gastroesophageal cancer Using an Antibody-drug conjugate for Residual Disease

Raghan Sundar, MD, PhD and Christopher Rodman, MD, Yale School of Medicine and Yale Cancer Center, New Haven CT

Chemotherapy with or without HAIP for unresectable liver only intrahepatic cholangiocarcinoma

Ronan Hsieh, MD, Washington State University College of Medicine and Swedish Cancer Institute, Seattle WA